Sorrento Therapeutics (LTS:0L85) ROCE %: -173.10% (As of Jun. 2023)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics ROCE %?

Sorrento Therapeutics LTS:0L85 12 ROCE % is -173.10% as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sorrento Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2023 was -173.10%.

Sorrento Therapeutics  (LTS:0L85) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sorrento Therapeutics ROCE % Related Terms

Sorrento Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics ROCE % Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.13 -64.59 -65.87 -90.94 -157.99

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -153.42 -80.77 -298.31 -257.94 -173.10
LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics ROCE % Calculation

Sorrento Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-553.173/( ( (694.818 - 139.453) + (472.84 - 327.922) )/ 2 )
=-553.173/( (555.365+144.918)/ 2 )
=-553.173/350.1415
=-157.99 %

Sorrento Therapeutics's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=-420.788/( ( (460.063 - 165.632) + (456.692 - 264.949) )/ 2 )
=-420.788/( ( 294.431 + 191.743 )/ 2 )
=-420.788/243.087
=-173.10 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -173.10% mean?
Sorrento Therapeutics (LTS:0L85) has a ROCE % of -173.10% as of Jun. 2023.
Is Sorrento Therapeutics' ROCE % too high?
Sorrento Therapeutics' current ROCE % is -173.10%. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' ROCE % compare to IMUX and OCUP?
Sorrento Therapeutics' ROCE % of -173.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sorrento Therapeutics's current ROCE % is -173.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current ROCE % of -173.10%. The current ROCE % is -173.10%. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current ROCE % is -173.10% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price